Anaptysbio, Inc. last reported quarterly results on May 12, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $25.6 million (-8.0% year over year) and diluted EPS of -$1.84. It usually reports 9–42 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–42 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
26
-8.0%
|
-53
-34.5%
|
-1.84
-43.8%
|
|
Jan 9, 2026
9 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
108
+151.1%
|
50
+327.8%
|
1.48
+337.4%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
76
+154.3%
|
15
+146.0%
|
0.52
+145.6%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
22
+102.9%
|
-39
+17.2%
|
-1.34
+21.6%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
28
+286.8%
|
-39
+10.5%
|
-1.28
+22.0%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
43
+378.8%
|
-22
+48.4%
|
-0.62
+60.9%
|
|
Nov 5, 2024
36 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
30
+804.7%
|
-33
+11.9%
|
-1.14
+19.1%
|
|
Aug 5, 2024
36 days after quarter end
|
Q2 FY2024
ended Jun 30, 2024
|
11
+217.1%
|
-47
-17.1%
|
-1.71
-14.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANAB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1370053
- Former names
- ANAPTYSBIO INC (until Jun 12, 2019); ANAPTYS BIOSCIENCES INC (until Nov 20, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.